CAR-T cell Therapy in B-cell Lymphoma

Abstract

B-cell lymphoma continues to be difficult to treat, with insignificant advances seen in more than two decades despite improvements in initial treatment strategies across its subtypes. Developing new targeted therapies which have acceptable safety and toxicity profiles is critical for better survival chances of the patients. Immunotherapy provides promising possibilities for patients with different B-cell lymphomas. CAR-T cell therapy has emerged as a new generation of powerful immunotherapy that has demonstrated high response in clinical trial for different B-cell lymphoma patients. The process involves adoptive transfer of T cells engineered ex vivo to be redirected to cancer cells. Recent clinical trials have provided promising safety and efficacy data for different B-cell lymphomas which have garnered enthusiasm in the scientific community. This review discusses the design of CAR-T cell therapy, its clinical trials and safety and efficacy strategies for successful clinical and commercial translation.